+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilars: US Access & Reimbursement

  • ID: 4705738
  • Report
  • Region: United States
  • 41 pages
  • Decision Resources Group
1 of 4

FEATURED COMPANIES

  • Boehringer Ingelheim's
  • Eli Lilly
  • Merck & Co
  • Pfizer
  • Sandoz
  • MORE
This US Biosimilars Access & Reimbursement report provides brand-level insight regarding the impact of payer policy on physician prescribing behavior in the US Biosimilars market so you can optimize your market access strategy and determine how to best position your biosimilar to specific stakeholders.

This report includes specific detail on the Biosimilars market access trends in the US, insight on how to maximize opportunity and limit barriers, analysis of key reimbursement decision-makers and the criteria they use, review of market access strategies used by competitors and highlights of where they succeeded or stumbled, detailed analysis of physician and payer perceptions based on physician surveys in-depth interviews with payers, and much more. This report is most relevant for professionals in market research, business intelligence, market access, brand teams, launch planning teams, business development & licensing. This report was published in May 2018.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Boehringer Ingelheim's
  • Eli Lilly
  • Merck & Co
  • Pfizer
  • Sandoz
  • MORE
1. Key Findings
2. Regulations and Guidance
3. Automatic Substitution
4. Seeking FDA Approvalas an interchangeable biological product
5. Reimbursement
6. Appendix
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Sandoz
  • Pfizer
  • Merck & Co
  • Eli Lilly
  • Boehringer Ingelheim's
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4705738
Adroll
adroll